BioPharmaSpec expands into Asia with new business development teams
Scientists in India and Asia-Pacific region will gain access to firm's characterisation services and speed up development of biosimilars
BioPharmaSpec, a contract research organisation (CRO) operating in Jersey, UK and Malvern, PA, US, which provides characterisation services for the biotechnology industry, is expanding its operations in Asia with business development teams in India and the Asia-Pacific region. This will allow scientists in the region to access the firm’s characterisation services and help accelerate the development of their biosimilars, the firm said.
BioPharmaSpec’s new teams will offer scientists in Asia access to technical experts, who will detail how the company’s expertise in mass spectrometry can be used to characterise critical features of biologics, providing them with a competitive edge for their biosimilar development.
Having already established relationships with major Asian firms developing biosimilars for the global market, BioPharmaSpec operates to robust quality standards, allowing full traceability without the associated costs of a Good Manufacturing Practice (GMP) system (which is not required for the early-stage characterisation and comparability of biosimilars). The company will also provide them with a clear understanding of what types of analysis and documentation are necessary to meet the requirements of European and US regulators.
'The structural characterisation of biopharmaceutical products is a broad and complicated process and a wide variety of techniques are involved in providing full characterisation information. For these reasons, I believe that our industry values proven technical expertise and product experience when selecting a CRO partner, especially when important decisions relating to comparability or biosimilarity are to be made,' said BioPharmaSpec Founder and CEO Andrew Reason.
